Takeda And Affymax Recall Anemia Drug | Chemical & Engineering News
Volume 91 Issue 9 | p. 23 | Concentrates
Issue Date: March 4, 2013

Takeda And Affymax Recall Anemia Drug

Department: Business
Keywords: biologics, peptides, safety, recall

Affymax and its Japanese partner Takeda Pharmaceutical have voluntarily recalled the anemia drug Omontys after about a year on the U.S. market. In late March 2012, FDA approved the PEGylated synthetic peptide as a treatment for anemia due to chronic kidney disease in adults. The recall came after five of 25,000 dialysis patients died as a result of serious hypersensitivity reactions. Omontys was the only product of 12-year-old Affymax, a business formerly owned by Glaxo­SmithKline. Omontys competed with other erythropoiesis-stimulating protein drugs, such as Amgen’s Epogen and Aranesp.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment